Use of a new diuretic agent (metolazone) in patients with edema and ascites.
D001201:Ascites / Q000188:drug therapy*; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000097:blood / Q000652:urine; D004232:Diuretics / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D004487:Edema / Q000188:drug therapy*; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000188:drug therapy; D008103:Liver Cirrhosis / Q000188:drug therapy; D009318:Natriuresis / Q000187:drug effects; D011188:Potassium / Q000097:blood / Q000652:urine; D011485:Protein Binding; D011799:Quinazolines / Q000627:therapeutic use*; D012964:Sodium / Q000097:blood; D013449:Sulfonamides / Q000627:therapeutic use*; D013997:Time Factors; D014508:Urea / Q000652:urine
D004232:Diuretics; D011799:Quinazolines; D013449:Sulfonamides; D005665:Furosemide; D014508:Urea; D012964:Sodium; D003404:Creatinine; D011188:Potassium